SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Parkway Properties Inc – ‘425’ on 4/29/16 re: Parkway Properties Inc – EX-10.3

On:  Friday, 4/29/16, at 8:30am ET   ·   Accession #:  1193125-16-566296   ·   File #:  1-11533

Previous ‘425’:  ‘425’ on 11/4/13   ·   Next:  ‘425’ on 4/29/16   ·   Latest:  ‘425’ on 5/4/16

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 4/29/16  Parkway Properties Inc            425                   13:11M  Parkway Properties Inc            RR Donnelley/FA

Business-Combination Transaction Communication   —   Rule 425
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 425         8-K                                                 HTML     72K 
 2: EX-2.1      Plan of Acquisition, Reorganization, Arrangement,   HTML   1.32M 
                          Liquidation or Succession                              
 3: EX-3.1      Articles of Incorporation/Organization or By-Laws   HTML      8K 
 4: EX-10.1     Material Contract                                   HTML     41K 
 5: EX-10.2     Material Contract                                   HTML     22K 
 6: EX-10.3     Material Contract                                   HTML     21K 
 7: EX-10.4     Material Contract                                   HTML     21K 
 8: EX-10.5     Material Contract                                   HTML     21K 
 9: EX-99.1     Miscellaneous Exhibit                               HTML     87K 
10: EX-99.2     Miscellaneous Exhibit                               HTML     37K 
11: EX-99.3     Miscellaneous Exhibit                               HTML     26K 
12: EX-99.4     Miscellaneous Exhibit                               HTML     14K 
13: EX-99.5     Miscellaneous Exhibit                               HTML    260K 


EX-10.3   —   Material Contract


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-10.3  

Exhibit 10.3

April 28, 2016

M. Jayson Lipsey

Parkway Properties, Inc.

Bank of America Center

390 North Orange Avenue, Suite 2400

Orlando, Florida 32801

Dear Mr. Lipsey,

This letter agreement (this “Letter Agreement”) memorializes our discussions regarding the terms and conditions of your employment from and following the consummation of the transactions (collectively, the “Transactions”) contemplated by the Agreement and Plan of Merger among Parkway Properties, Inc., Parkway Properties LP, Cousins Properties Incorporated and Clinic Sub Inc., dated as of the date hereof (the “Merger Agreement”). For purposes of this Letter Agreement, terms that are capitalized but not defined herein shall have the meanings set forth in the Merger Agreement.

As you know, the Merger Agreement contemplates that, immediately following the consummation of the Merger and the Reorganization, Clinic will distribute, on a pro rata basis to the stockholders of Clinic, all of the shares of HoustonCo (the “Houston Distribution”), and that you will be offered the role of Executive Vice President and Chief Operating Officer of HoustonCo in connection with the Houston Distribution.

You agree that, if you are offered the role of Executive Vice President and Chief Operating Officer of HoustonCo in connection with the Houston Distribution pursuant either to the assignment of your Employment Agreement (defined below) as in effect as of the date hereof (and as modified hereby) to HoustonCo or to terms of a written employment agreement the terms of which are at least as favorable to you as your Employment Agreement (defined below) as in effect as of the date hereof, you shall not have a basis for asserting, and shall be deemed to have waived, any entitlement to terminate your employment under clauses (ii), (iii) or (iv) of the second sentence, as well as the final sentence, of Section 5(a)(4) of the Employment Agreement by and between Pharmacy and you, dated as of October 25, 2013 and amended as of June 15, 2015 (the “Employment Agreement”), as a result of the consummation of the Transactions or any changes to the terms and conditions (including, without limitation, the location) of your employment that result from the Transactions. Without limiting the generality of the foregoing, you agree that Pharmacy or Clinic, as applicable, and its Affiliates may assign all of their obligations under the Employment Agreement and/or this Letter Agreement to HoustonCo and its Affiliates. For purposes of determining whether the terms of a new employment agreement are at least as favorable as the terms of your Employment Agreement, any special one-time equity award may be disregarded.

You acknowledge and agree that the waiver contemplated by the preceding paragraph is material to Clinic’s and Pharmacy’s willingness to consummate the Transactions and that good and valuable consideration will be provided, directly or indirectly, to you in


connection with the Transactions, including without limitation: (a) the accelerated vesting of certain Pharmacy Partnership LTIP Units upon the consummation of the Transactions, (b) exchange of unvested Pharmacy Partnership LTIP Units, if any, into time-vesting Pharmacy Equity Awards immediately prior to the consummation of the Transactions, which shall partially vest upon the consummation of the Transactions and shall partially be assumed, (c) assumption of those Pharmacy Equity Awards that are stock options, and (d) your continued employment with HoustonCo and its Affiliates following the consummation of the Transactions as the Executive Vice President and Chief Operating Officer under the terms of the Employment Agreement (subject to the waiver described above) or, if applicable, a new employment agreement satisfying the conditions described in paragraph three of this Letter Agreement.

Furthermore, in connection with consummation of the Transactions, you acknowledge and agree to the following:

 

  1. That any annual incentive award payable to you for calendar year 2016 shall, notwithstanding any contrary provision of your Employment Agreement, be subject to the sole discretion of Clinic and its Affiliates (which for this purpose, includes HoustonCo, whether before or after the Houston Distribution),

 

  2. That the Pharmacy Equity Awards and Pharmacy Partnership LTIP Units listed on Exhibit A may be converted into an equal number of Pharmacy RSU Awards immediately prior to consummation of the Transactions, generally subject to the terms and conditions of your current time-based Pharmacy RSU Awards, but vesting in four equal tranches, with twenty-five percent (25%) becoming vested on the date of consummation of the Transactions, and twenty-five percent (25%) each becoming vested on the first, second, and third anniversaries of the date of consummation of the Transactions; and

 

  3. That in connection with the Transactions, unless Clinic waives this requirement in writing, you will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any HoustonCo common shares you hold by reason of a Pharmacy Equity Award or a Pharmacy Partnership LTIP Unit that becomes fully vested as a result of the Transactions, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such common shares, whether any such transaction is to be settled by delivery of HoustonCo common shares or other HoustonCo securities, in cash or otherwise, for sixty (60) days after consummation of the Transactions. You further agree to execute such agreements and instruments as may be reasonably requested by Clinic or HoustonCo to give further effect to this undertaking.

This Letter Agreement, together with the Employment Agreement, constitute the entire agreement between the parties hereto with respect to the subject matter hereof. No provision of this Letter Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in a writing signed by you, Clinic, and Pharmacy. This Letter Agreement shall be governed, construed, and interpreted under the laws of the State of New York without reference to its principles of conflicts of laws.

 

2


If the Effective Time does not occur, this Letter Agreement shall be null and void ab initio.

From and following the Effective Time, your employment shall continue to be at will and may be terminated by either you or HoustonCo or its Affiliates at any time, without prior notice and for any or no reason.

We believe that you and HoustonCo will have a promising future. Please acknowledge your agreement to the terms of this Letter Agreement by your signature below.

Sincerely,

 

Cousins Properties Incorporated
By:  

/s/ Pamela F. Roper

Name:   Pamela F. Roper
Title:   Senior Vice President, General Counsel and Corporate Secretary

 

3


By:  

/s/ James R. Heistand

  Name:   James R. Heistand
  Title:   President and Chief Executive Officer
By:  

/s/ Jeremy R. Dorsett

  Name:   Jeremy R. Dorsett
  Title:   Executive Vice President, General Counsel and Secretary

 

Acknowledged and Agreed:  

/s/ M. Jayson Lipsey

   

April 28, 2016

 
M. Jayson Lipsey     Date  


EXHIBIT A

 

Name

   Number     

Class

M. Jayson Lipsey

     23,760       2016 Time-Based Pharmacy RSU Awards

M. Jayson Lipsey

     11,553       2015 Time-Based Pharmacy RSU Awards

M. Jayson Lipsey

     6,000       2014 Time-Based Pharmacy RSU Awards

M. Jayson Lipsey

     2,492       2013 (March) Time-Based Pharmacy RSU Awards

M. Jayson Lipsey

     15,722       2013 (October) Time-Based Pharmacy RSU Awards

M. Jayson Lipsey

     23,106       2015 Pharmacy Partnership LTIP Units

M. Jayson Lipsey

     18,000       2014 Pharmacy Partnership LTIP Units
  

 

 

    

Total

     100,633       New Pharmacy RSU Awards
  

 

 

    

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘425’ Filing    Date    Other Filings
Filed on:4/29/16425
4/28/16
6/15/158-K
10/25/134,  8-K
 List all Filings 
Top
Filing Submission 0001193125-16-566296   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 6:32:24.2am ET